pharmaceutics

IMPACT FACTOR 5.5

Indexed in: PubMed

CITESCORE 10.0

an Open Access Journal by MDPI

Nano-Enabled Therapeutics for Modulation of Immune Function

Guest Editors:

Dr. Christopher David
Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool L7 3NY, UK

Dr. Marco Giardiello
Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, UK

Deadline for manuscript submissions:
closed (30 November 2023)

Message from the Guest Editors

Nano-enabled therapeutics use nanoparticles to enhance the delivery and efficacy of therapeutic agents which, in turn, have the capability to modulate the immune system through enhancement or suppression. Nanoparticles are effective at targeting immune cells, achieved through surface modifications that allow binding to specific receptors on immune cells, or by exploiting physicochemical properties allowing tissue penetration. Furthermore, nanoparticles have been utilized to deliver immunomodulatory agents to specific sites in the body. This has been achieved by encapsulating the agent within the nanoparticle or by conjugating the agent to the nanoparticle surface. These methods have been successful in modulating the immune response and have the potential to be used to treat a variety of immune-related diseases including cancer, autoimmune disorders, and infectious diseases. The potential for nano-enabled therapeutics to improve the delivery and efficacy of therapeutic agents while minimizing side effects is significant.

This Special Issue seeks to highlight current progress in the development and implementation of nano-enabled therapeutics for modulation of immune function.

pharmaceutics

IMPACT FACTOR 5.5 | Indexed in: PubMed | CITESCORE 10.0

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
𝕏@MDPIpharma